These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203 [TBL] [Abstract][Full Text] [Related]
3. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692 [TBL] [Abstract][Full Text] [Related]
4. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. Bethke TD; Böhmer GM; Hermann R; Hauns B; Fux R; Mörike K; David M; Knoerzer D; Wurst W; Gleiter CH J Clin Pharmacol; 2007 Jan; 47(1):26-36. PubMed ID: 17192499 [TBL] [Abstract][Full Text] [Related]
5. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614 [TBL] [Abstract][Full Text] [Related]
6. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106 [TBL] [Abstract][Full Text] [Related]
7. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. Eckermann G; Lahu G; Nassr N; Bethke TD J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799 [TBL] [Abstract][Full Text] [Related]
9. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. Nassr N; Lahu G; Hünnemeyer A; von Richter O; Knoerzer D; Reutter F; Zech K; Hermann R J Clin Pharmacol; 2007 May; 47(5):660-6. PubMed ID: 17374735 [No Abstract] [Full Text] [Related]
10. Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults. Bethke TD; Huennemeyer A; Lahu G; Lemmer B Chronobiol Int; 2010 Oct; 27(9-10):1843-53. PubMed ID: 20969527 [TBL] [Abstract][Full Text] [Related]
11. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624 [TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics of roflumilast in children and adolescents. Neville KA; Szefler SJ; Abdel-Rahman SM; Lahu G; Zech K; Herzog R; Bethke TD; Gleason MC; Kearns GL J Clin Pharmacol; 2008 Aug; 48(8):978-85. PubMed ID: 18508947 [TBL] [Abstract][Full Text] [Related]
13. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Karish SB; Gagnon JM Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669 [TBL] [Abstract][Full Text] [Related]
14. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786 [TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639 [TBL] [Abstract][Full Text] [Related]
16. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. Schmidt BM; Kusma M; Feuring M; Timmer WE; Neuhäuser M; Bethke T; Stuck BA; Hörmann K; Wehling M J Allergy Clin Immunol; 2001 Oct; 108(4):530-6. PubMed ID: 11590377 [TBL] [Abstract][Full Text] [Related]
17. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Bousquet J; Aubier M; Sastre J; Izquierdo JL; Adler LM; Hofbauer P; Rost KD; Harnest U; Kroemer B; Albrecht A; Bredenbröker D Allergy; 2006 Jan; 61(1):72-8. PubMed ID: 16364159 [TBL] [Abstract][Full Text] [Related]
18. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871 [TBL] [Abstract][Full Text] [Related]
19. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389 [TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]